Heart Failure
Heart failure, also known as congestive heart failure, is a progressive condition where the heart cannot pump enough blood to oxygenate the body's tissues, typically resulting in symptoms like shortness of breath, fatigue, and leg swelling. It is a leading cause of hospitalization for patients over 65 in the U.S. and is often caused by other heart conditions that alter the heart's structure and function.
Health Outcomes
- Achieved Clinically Significant Systolic Blood Pressure Reduction
- Altered Catecholamine Level
- Association with Sarcopenia
- Attenuated Blood Pressure (Inactivated Cells Only)
- Changed Bicarbonate Level
- Changed Heart Rate
- Changed QT Interval Length
- Changed Walking Cadence
- Decreased Oxygen Saturation
- Decreased Oxygenated Hemoglobin Level
- Delayed Disease Progression
- Developed Endocarditis
- Developed Polymorphic Ventricular Tachycardia
- Enhanced Antioxidant Response
- Enhanced Cell Viability Under Oxidative Stress
- Enhanced Folate Synthesis
- Extended Cardiac Transplant Survival
- Extended Lifespan in Caenorhabditis elegans
- Identified ACE-Inhibitory Peptides
- Improved 6-Meter Walk Performance
- Improved 6-Minute Walk Test Distance
- Improved 6-minute Walking Distance
- Improved Activities of Daily Living Score
- Improved Aerobic Endurance Performance
- Improved Aerobic Power
- Improved Aging-Related Changes
- Improved Anaerobic Threshold
- Improved Ang-(1-7)/Ang II Ratio
- Improved Angiogenesis
- Improved Antihypertensive Activity
- Improved Antioxidant Levels
- Improved Antioxidative Capacity
- Improved Antioxidative Response
- Improved Arginine Metabolism
- Improved Arginine to Asymmetric Dimethylarginine Ratio
- Improved Arterial Oxygen Saturation
- Improved Blood Pressure
- Improved Brachial Artery Diameter
- Improved Breath Perception
- Improved CVD-Related Symptom
- Improved Cardiac Baroreflex Sensitivity
- Improved Cardiac Function
- Improved Cardiac Histopathology
- Improved Cardiac Muscle Contractile Performance
- Improved Cardiac Muscle Structural Integrity
- Improved Cardiac Output
- Improved Cardioprotective Activity
- Improved Cardiopulmonary Exercise Testing
- Improved Cardiorespiratory Fitness
- Improved Cardiovascular Disease Outcomes
- Improved Cardiovascular Function
- Improved Cardiovascular Health
- Improved Clinical Activity
- Improved Clinical Efficacy
- Improved Clinical Outcomes
- Improved Clinical Response
- Improved Clinical Success
- Improved Combined Cardiopulmonary Outcomes
- Improved Constant Work Rate Exercise Time
- Improved Critical Velocity
- Improved Cycling Endurance
- Improved Cytoprotection During Oxidative Stress
- Improved DASH Score
- Improved Daily Activity Participation
- Improved Diastolic Function
- Improved Disease Control
- Improved Disease Management
- Improved Distance Traveled
- Improved Dyspnea
- Improved Ejection Fraction
- Improved Endothelial Function
- Improved Endothelial Function Biomarker
- Improved Endothelial Health Marker Level
- Improved Endothelial Reactivity
- Improved Endothelium-Dependent Vasodilation
- Improved Endothelium-Dependent Vasodilation in Resistance Arteries
- Improved Endothelium-Independent Microvascular Vasodilation
- Improved Endurance
- Improved Endurance Exercise Performance
- Improved Endurance Performance
- Improved Endurance Power
- Improved Estimated VO2max
- Improved Event-Free Survival
- Improved Exercise Capacity
- Improved Exercise Duration
- Improved Exercise Endurance
- Improved Exercise Function
- Improved Exercise Performance
- Improved Exercise Recovery
- Improved Exercise Stress Test Grade
- Improved Exercise Test Performance
- Improved Exercise Time to Exhaustion
- Improved Exercise Tolerance
- Improved Exercise-Onset Vasodilator Kinetics
- Improved Fatigue
- Improved Fatigue Symptoms
- Improved Fatigue Threshold
- Improved Fatigue Tolerance
- Improved Flow-Mediated Dilatation
- Improved Flow-Mediated Dilation
- Improved Fractional Shortening
- Improved Function
- Improved Function Score
- Improved Functional Ability
- Improved Functional Activity
- Improved Functional Capacity
- Improved Functional Exercise Capacity
- Improved Functional Outcome
- Improved Functional Properties of Food
- Improved Functional Status
- Improved GDF-15 Level
- Improved General Activity
- Improved Global Clinical Status
- Improved Global Quality of Life
- Improved Health Condition
- Improved Health Outcomes
- Improved Health Status
- Improved Heart Failure Symptom
- Improved Heart Rate
- Improved Heart Rate Recovery
- Improved Heart Rate Variability
- Improved Hemodynamic Parameter
- Improved Hemodynamic Stability
- Improved Homeostasis
- Improved Hospital Discharge
- Improved Human Health
- Improved Inotropic Function
- Improved Inspiratory Muscle Oxygenation
- Improved Intermittent Exercise Performance
- Improved Lactate Threshold
- Improved Left Ventricular E'/A' Ratio
- Improved Left Ventricular Ejection Fraction
- Improved Left Ventricular Global Longitudinal Strain
- Improved Leg Extension Strength
- Improved Life's Essential 8 Score
- Improved Limited Distance Test Performance
- Improved Lower Body Endurance
- Improved Lower Body Muscular Endurance
- Improved Lower Limb Peak Power
- Improved Maximal Exercise Capacity
- Improved Maximal Inspiratory Pressure
- Improved Maximal Oxygen Capacity
- Improved Maximal Oxygen Consumption
- Improved Maximal Oxygen Uptake
- Improved Maximal Power
- Improved Maximal Walking Performance
- Improved Maximal Workload or Power Output
- Improved Mean Arterial Pressure
- Improved Mean Power Output
- Improved Medication Adherence
- Improved Myocardial Strain
- Improved Myocardial Strain Rate
- Improved Overall Patient Outcomes
- Improved Oxidative Metabolism Regulation
- Improved Oxygen Saturation
- Improved Pacing
- Improved Passive Limb Movement Blood Flow
- Improved Patient Satisfaction
- Improved Peak Oxygen Intake
- Improved Perceived Exertion
- Improved Phase Angle
- Improved Physical Activity Initiation
- Improved Physical Activity Level
- Improved Physical Domain Score
- Improved Physical Function
- Improved Physical Health
- Improved Physical Health-Related Quality of Life
- Improved Physical Performance
- Improved Physical Quality of Life
- Improved Physical Role Limitation
- Improved Physical Work Capacity
- Improved Physiological Parameters
- Improved Physiological Response
- Improved Post-Myocardial Infarction Outcome
- Improved Prognosis
- Improved Pulse Wave Velocity
- Improved Quality of Life
- Improved Quality of Life Score
- Improved Reactive Hyperemia Index
- Improved Recovery Rate
- Improved Right Ventricular Function
- Improved Role Physical
- Improved Role Physical Health
- Improved Run Time
- Improved Serum Biomarkers
- Improved Six Minute Walking Distance
- Improved Six-Minute Walk Distance
- Improved Six-Minute Walk Test
- Improved Sprint Repeat Task Performance
- Improved Stress-Strain Index
- Improved Stroke Volume
- Improved Survival
- Improved Survival Rate Against Influenza Virus
- Improved Survival Rate Under Nitrite Stress
- Improved Survival Time
- Improved Survival at 24 Months
- Improved Symptom Control
- Improved Symptoms of Chronic Condition
- Improved Systolic Function
- Improved Systolic Myocardial Velocity
- Improved TBARS Levels
- Improved Time to Exhaustion
- Improved Tissue Inhibitor of Matrix Metalloproteinase-1 Level
- Improved Tissue Oxygen Saturation Index
- Improved Traditional Chinese Medicine Syndrome Effective Rate
- Improved Treatment Compliance
- Improved Treatment Effective Rate
- Improved Troponin T Level
- Improved Urine Volume
- Improved VO2max
- Improved Vagal Reactivation
- Improved Vascular Biomarker
- Improved Vascular Conductance
- Improved Vascular Function
- Improved Vascular Reactivity
- Improved Vasodilation
- Improved Walking Distance
- Improved Wingate Peak Power
- Improved Work Capacity
- Incidence of Death
- Increased 6-Minute Walk Test Distance
- Increased ACE Inhibitor Activity
- Increased Antihypertensive Peptide Production
- Increased Arginine/ADMA Ratio
- Increased Benefit Rate
- Increased Blood Bicarbonate Level
- Increased Blood Lactate Level
- Increased Blood Urea Level
- Increased Days Alive and Out of Hospital
- Increased Deoxygenated Hemoglobin Level
- Increased Diuresis
- Increased Endothelial Progenitor Cell Count
- Increased Endurance Swimming Time
- Increased Erythropoietin Level
- Increased Exercise Capacity
- Increased FGF23 Level
- Increased Hemodynamic Disturbance
- Increased Hepatic Vein Flow
- Increased Hospital Admissions
- Increased Hyperkalemia
- Increased Invasive Interventions Requirement
- Increased L-Arginine to ADMA Ratio
- Increased L-arginine Level
- Increased LA/ADMA Ratio
- Increased Lactate Level
- Increased Lactate Levels
- Increased Leg Circumference
- Increased Length
- Increased Low Frequency Power
- Increased Maximal Incremental Cycling Capacity
- Increased Mortality
- Increased Mortality Rate
- Increased Nitrate Level
- Increased Nitric Oxide Metabolite Level
- Increased Occurrence of Serious Adverse Events
- Increased Organ Weights
- Increased Oxidative Stress Tolerance
- Increased Oxygen Uptake at Ventilatory Threshold
- Increased Peak Oxygen Uptake
- Increased Perceived Exertion
- Increased Plasma Haptoglobin Levels
- Increased Potassium Level
- Increased Power Output at Ventilatory Threshold
- Increased Pro-inflammatory Cytokine TNFα Levels
- Increased Production of ACE-Inhibitory Peptides
- Increased Production of Bioactive Peptides with Angiotensin Converting Enzyme Inhibitory Activity
- Increased QTc Interval
- Increased Rating of Perceived Exertion
- Increased Recumbent Length
- Increased Risk of Cardiac Arrhythmias
- Increased SalA-like Inhibitory Activity
- Increased Satisfaction
- Increased Serum Nitric Oxide Level
- Increased Soluble Vascular Cell Adhesion Molecule-1 Level
- Increased Systolic Blood Pressure
- Increased TGFB1 Level
- Increased Time to Ventilatory Threshold
- Increased Total Body Water
- Increased Total L-Carnitine Level
- Increased Type 1 Collagen Synthesis
- Increased VO2 Max
- Increased Velocity-Time Integral
- Increased miRNA-21 Expression
- Inhibited Platelet Aggregation
- Maintained Physical Performance
- Mitigated Adverse Physiological Processes
- Mitigated Cardiac Injury from Myocardial Infarction
- Modulated Anterograde Blood Flow
- Modulated Anterograde Shear Rate
- Modulated Arterial Diameter
- Modulated Retrograde Shear Rate
- Neutralized Reactive Oxygen Species
- No Change in Major Cardiovascular Event
- No Difference in Adverse Events
- Normalized Serum IL-1β Levels
- Preserved Cardiac Function
- Prevented Hypertension
- Prevented Sepsis
- Prolonged Cardiac Allograft Survival
- Prolonged Median Survival Time
- Prolonged QT Interval
- Reduced 50-Meter Sprint Time
- Reduced ACE Activity
- Reduced Acute Kidney Injury
- Reduced Acute Kidney Injury Rate
- Reduced Adipose Tissue Wasting
- Reduced Adverse Physiometabolic Effects
- Reduced Angiotensin I-Converting Enzyme Activity
- Reduced Aortic Pressure
- Reduced Aortic Pulse Pressure
- Reduced Aortic Stiffness
- Reduced Aortic Systolic Blood Pressure
- Reduced Apelin Gene Expression
- Reduced Apolipoprotein B-100 to Apolipoprotein A-1 Ratio
- Reduced Appetite Changes
- Reduced Arginine Level
- Reduced Arterial Stiffness
- Reduced Asymmetric Dimethylarginine Level
- Reduced Augmented Pressure
- Reduced Backward Wave Amplitude
- Reduced Bicarbonate Level
- Reduced Blood Pressure
- Reduced Borg Scale Score
- Reduced Cardiac Arrest Risk
- Reduced Cardiac Arrhythmia
- Reduced Cardiac Biochemical Marker
- Reduced Cardiac Damage
- Reduced Cardiac Event
- Reduced Cardiac Function
- Reduced Cardiac Hypertrophy
- Reduced Cardiac Injury
- Reduced Cardiac Output
- Reduced Cardiovascular Disease Incidence
- Reduced Cardiovascular Disease Mortality
- Reduced Cardiovascular Disease Symptom
- Reduced Cardiovascular Dysfunction
- Reduced Cardiovascular Event
- Reduced Cardiovascular Event Rate
- Reduced Cardiovascular Mortality
- Reduced Cause-Specific Mortality
- Reduced Central Blood Pressure
- Reduced Chloride Level
- Reduced Coenzyme Q10 Level
- Reduced Community Healthcare Costs
- Reduced Composite Score
- Reduced Contrast-Induced Acute Kidney Injury
- Reduced Coxsackievirus B3 Activity
- Reduced Coxsackievirus B3 Viral Load
- Reduced Creatinine Clearance
- Reduced Cumulative Morbidity Rates
- Reduced Cumulative Mortality
- Reduced Daytime Maximum Heart Rate
- Reduced Death Rate
- Reduced Decompensation
- Reduced Deoxygenated Hemoglobin Level
- Reduced Dephosphorylated-Uncarboxylated Matrix Gla Protein Level
- Reduced Disability
- Reduced Dobutamine Duration
- Reduced Drug Concentration
- Reduced Duration of Dobutamine Use
- Reduced Dyspnea
- Reduced Dyspnea Score
- Reduced Dyspnea Symptoms
- Reduced Edema
- Reduced Emergency Care Unit Stay Duration
- Reduced Emergency Visit
- Reduced Exercise Metabolic Intensity
- Reduced Exertion Perception
- Reduced Exertional Dyspnea
- Reduced Exhaustion During Stress Test
- Reduced Extremity Swelling
- Reduced False Alarms
- Reduced Fat-Free Mass
- Reduced Fatigue Decrement
- Reduced Fatigue Severity
- Reduced Flow-Mediated Dilation
- Reduced Forearm Blood Flow Response to Acetylcholine
- Reduced Forward Wave Amplitude
- Reduced Free Triiodothyronine
- Reduced Functional Iron Deficiency
- Reduced Graft Rejection
- Reduced HIF-1α Level
- Reduced HIF-1α Protein Level
- Reduced Half Relaxation Time
- Reduced Healthcare Costs
- Reduced Heart Rate Increase
- Reduced Heart Rate Variability
- Reduced Heat Stress
- Reduced Hospital Admission Rate
- Reduced Hospital Mortality Rate
- Reduced Hospital Readmission Risk
- Reduced Hospital Stay
- Reduced Hospitalization
- Reduced Hospitalization Day
- Reduced Hospitalization Duration
- Reduced Hospitalization Frequency
- Reduced Hospitalization Rate
- Reduced Hospitalization Requirement
- Reduced Hypertension
- Reduced ICAM-1 Level
- Reduced In-hospital Mortality
- Reduced Incidence of Cardiovascular Disease
- Reduced Incidence of Influenza
- Reduced Inotropic Support Requirement
- Reduced Intensive Care Unit Length of Stay
- Reduced Intensive Care Unit Mortality
- Reduced Intensive Care Unit Outcome
- Reduced Interleukin-15 Levels
- Reduced Interventricular Septal Thickness in Diastole
- Reduced Iron-Corrected T1
- Reduced LF/HF Ratio
- Reduced Lactate Levels
- Reduced Lean Mass
- Reduced Left Ventricular Ejection Fraction Decline
- Reduced Left Ventricular End-Diastolic Volume
- Reduced Left Ventricular Hypertrophy
- Reduced Length of Hospitalization
- Reduced Length of Stay
- Reduced Life Threatening Complication
- Reduced Lifespan
- Reduced Maximum Heart Rate
- Reduced Mean Arterial Pressure
- Reduced Mortality
- Reduced Mortality Rate
- Reduced Mortality Rate Before Discharge
- Reduced Mortality Rate under Stress
- Reduced Muscle Deoxygenation Rate
- Reduced Muscular Endurance
- Reduced Myeloperoxidase (MPO) Concentration
- Reduced Myeloperoxidase Levels
- Reduced Myocardial Injury Cytokines
- Reduced NSAID Consumption
- Reduced NT-proBNP Level
- Reduced Need for Continuous Renal Replacement Therapy
- Reduced Nitric Oxide Level
- Reduced Nocturia
- Reduced Nocturnal Frequency
- Reduced Non-Infectious Complication Morbidity
- Reduced Non-Programmed Medical Visits
- Reduced Omission Errors
- Reduced One-Year All-Cause Mortality
- Reduced One-Year Arrhythmia
- Reduced Organ Dysfunction
- Reduced Organ Failure Severity
- Reduced Overall Complication
- Reduced Overall Mortality Rate
- Reduced Oxygen Consumption during Exercise
- Reduced Oxygen Saturation Decrease
- Reduced Oxygen Support Requirement
- Reduced PSE Index
- Reduced Palpitation
- Reduced Palpitation Symptoms
- Reduced Physical Activity
- Reduced Physiological Impairments
- Reduced Platelet Function Marker Level
- Reduced Postoperative Atrial Fibrillation
- Reduced Postoperative Complications
- Reduced Potassium Level
- Reduced Power
- Reduced Protein Oxidation
- Reduced Pulse Pressure
- Reduced Quadriceps Muscle Cross-Sectional Area
- Reduced Rating of Perceived Exertion
- Reduced Recovery Rate
- Reduced Renal Sympathetic Activity
- Reduced Respiratory Exchange Ratio
- Reduced Rowing Performance
- Reduced Saturated Fatty Acids in Breast Meat
- Reduced Sequential Organ Failure Assessment Score
- Reduced Serious Adverse Events
- Reduced Serum Potassium Level
- Reduced Short-term Mortality
- Reduced Shortness of Breath
- Reduced Soluble Fas/Fas Ligand Ratio
- Reduced Stroke Volume
- Reduced Survival Rate
- Reduced Swimming Time
- Reduced Sympathetic Hyperactivity
- Reduced Taste Disturbance Incidence
- Reduced Thigh Circumference
- Reduced Time Trial Completion Time
- Reduced Time to Complete Uphill Time Trial
- Reduced Tissue Inhibitor of Metalloproteinase 1 Level
- Reduced Total Triiodothyronine
- Reduced Treatment Costs
- Reduced Tricuspid Regurgitation
- Reduced Triiodothyronine Level
- Reduced Trimethylamine N-oxide Level
- Reduced Trimethylamine N-oxide Levels
- Reduced Troponin I Level
- Reduced Troponin T Level
- Reduced Trypanosoma cruzi Parasitaemia
- Reduced Unplanned Medical Re-presentations
- Reduced Unplanned Re-presentation
- Reduced Vascular Calcification
- Reduced Vascular Endothelial Growth Factor Level
- Reduced Vasoactive Drug Duration
- Reduced Walking Time
- Reduced hsCRP Level
- Reduced mDF Score
- Regulated Blood Pressure
- Regulated Blood miRNA Expression
- Regulated Oxidative Stress
- Resolved Pleural Effusion
- Slower Weight Gain
- Stabilized Disease Progression
- Unchanged Survival Rate